JNJ
$133.82
Johnson & Johnson
($1.19)
(.88%)
Earnings Details
1st Quarter March 2017
Tuesday, April 18, 2017 6:40:00 AM
Tweet Share Watch
Summary

Johnson & Johnson Beats

Johnson & Johnson (JNJ) reported 1st Quarter March 2017 earnings of $1.83 per share on revenue of $17.8 billion. The consensus earnings estimate was $1.77 per share on revenue of $18.0 billion. The Earnings Whisper number was $1.78 per share. Revenue grew 1.6% on a year-over-year basis.

The company said it now expects 2017 earnings of $7.00 to $7.15 per share on revenue of $75.40 billion to $76.10 billion. The company's previous guidance was earnings of $6.93 to $7.08 per share on revenue of $74.10 billion to $74.80 billion and the current consensus earnings estimate is $7.03 per share on revenue of $74.67 billion for the year ending December 31, 2017.

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of products in the health care field within its Consumer, Pharmaceutical and Medical Devices, and Diagnostics business segments.

Results
Reported Earnings
$1.83
Earnings Whisper
$1.78
Consensus Estimate
$1.77
Reported Revenue
$17.77 Bil
Revenue Estimate
$18.00 Bil
Growth
Earnings Growth
Revenue Growth
Power Rating
Grade
Earnings Release

Johnson & Johnson Reports 2017 First-Quarter Results:

Johnson & Johnson (JNJ) today announced sales of $17.8 billion for the first quarter of 2017, an increase of 1.6% as compared to the first quarter of 2016. Operational sales results increased 2.0% and the negative impact of currency was 0.4%. Domestic sales increased 0.6%. International sales increased 2.8%, reflecting operational growth of 3.6% and a negative currency impact of 0.8%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 1.2%, domestic sales decreased 0.7% and international sales increased 3.4%.*

https://mma.prnewswire.com/media/403394/Johnson_and_Johnson_Logo.jpg

Net earnings and diluted earnings per share for the first quarter of 2017 were $4.4 billion and $1.61, respectively. First-quarter 2017 net earnings included after-tax intangible amortization expense of approximately $0.2 billion and a charge for after-tax special items of approximately $0.4 billion. First-quarter 2016 net earnings included after-tax intangible amortization expense of approximately $0.2 billion and a charge for after-tax special items of approximately $0.2 billion. Excluding after-tax intangible amortization expense and special items, adjusted net earnings for the current quarter were $5.0 billion and adjusted diluted earnings per share were $1.83, representing increases of 3.8% and 5.8%, respectively, as compared to the same period in 2016.* On an operational basis, adjusted diluted earnings per share also increased 7.5%.* A reconciliation of non-GAAP financial measures is included as an accompanying schedule.

"Johnson & Johnson’s first-quarter results are in line with our expectations and we are confident we will achieve the full-year financial guidance we established at the beginning of the year," said Alex Gorsky, Chairman and Chief Executive Officer. "The pending acquisition of Actelion demonstrates our ongoing commitment to bringing innovation to patients with significant unmet needs, and provides a unique opportunity for us to expand our portfolio with leading, differentiated in-market medicines and promising late-stage products. We look forward to the associates from Actelion joining the Johnson & Johnson Family of Companies."

The Company is now including the estimated impact of the Actelion transaction in its financial guidance. As such, the Company increased its sales guidance for the full-year 2017 to $75.4 billion to $76.1 billion. Additionally, the Company increased its adjusted earnings guidance for full-year 2017 to $7.00 - $7.15 per share.*

Worldwide Consumer sales of $3.2 billion for the first quarter 2017 represented an increase of 1.0% versus the prior year, consisting of an operational increase of 0.8% and a positive impact from currency of 0.2%. Domestic sales increased 4.1%; international sales decreased 1.3%, which reflected an operational decrease of 1.6% and a positive currency impact of 0.3%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales decreased 2.3%, domestic sales decreased 2.9% and international sales decreased 1.9%*.

Worldwide operational results, excluding the net impact of acquisitions and divestitures, were negatively impacted by LISTERINE? oral care products, baby care products, and wound care products, partially offset by growth in over-the-counter products, including domestic TYLENOL? analgesics.

Worldwide Pharmaceutical sales of $8.2 billion for the first quarter 2017 represented an increase of 0.8% versus the prior year with an operational increase of 1.4% and a negative impact from currency of 0.6%. Domestic sales decreased 1.3%; international sales increased 4.1%, which reflected an operational increase of 5.6% and a negative currency impact of 1.5%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 2.2%, domestic sales decreased 0.4% and international sales increased 6.1%.*

Worldwide operational results, excluding the net impact of acquisitions and divestitures, were driven by new products and the strength of core products. Strong growth in new products include DARZALEX? (daratumumab), for the treatment of patients with multiple myeloma and IMBRUVICA? (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer. Additional contributors to operational sales growth included STELARA? (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases, and INVEGA? SUSTENNA?/XEPLION?/TRINZA? (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults. Sales growth was negatively impacted by a positive adjustment of rebate accruals in the first quarter of 2016, which did not occur to the same degree in the first quarter of 2017.

During the quarter, the Company announced a definitive agreement to acquire Actelion Ltd., a leading biopharmaceutical company, for approximately $30 billion. The public tender offer for Actelion has been declared successful based on the number of shares tendered and regulatory approval has been obtained in six of seven jurisdictions in which the company filed for such approval, with antitrust approval from the European Commission pending. The transaction is expected to close in the second quarter of 2017, subject to the satisfaction of remaining closing conditions.

Also in the quarter, the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommending broadening the existing marketing authorization for DARZALEX? (daratumumab) for use in combination with lenalidomide and dexamethasone; or bortezomib and dexamethasone, for the treatment of multiple myeloma in patients who have received at least one prior therapy. A supplemental New Drug Application was submitted to the U.S. Food and Drug Administration for IMBRUVICA? (ibrutinib) for the treatment of chronic Graft-Versus-Host Disease after failure of one or more lines of systemic therapy.

In April, subsequent to the quarter, a marketing authorization application was submitted to the European Medicines Agency for ZYTIGA? (abiraterone acetate) to expand the existing indication to include treatment of men with newly diagnosed high-risk metastatic hormone sensitive prostate cancer.

Worldwide Medical Devices sales of $6.3 billion for the first quarter 2017 represented an increase of 3.0% versus the prior year consisting of an operational increase of 3.4% and a negative currency impact of 0.4%. Domestic sales increased 2.2%; international sales increased 3.8%, which reflected an operational increase of 4.7% and a negative currency impact of 0.9%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 1.7%, domestic sales decreased 0.2% and international sales increased 3.7%.*

Worldwide operational results, excluding the net impact of acquisitions and divestitures, were driven by electrophysiology products in the Cardiovascular business; ACUVUE? contact lenses in the Vision Care business and endocutters in the Advanced Surgery business, partially offset by declines in the Diabetes Care business.

During the quarter, the company completed the acquisition of Abbott Medical Optics, a wholly-owned subsidiary of Abbott and global leader in ophthalmic surgery, for approximately $4.3 billion.

Additionally, the acquisitions of Megadyne Medical Products, Inc., a privately held medical device company that develops, manufactures and markets electrosurgical tools, and Torax Medical Inc., a privately held medical device company that manufactures and markets the LINX(TM) Reflux Management System for the surgical treatment of gastroesophageal reflux disease, were completed.

In April, subsequent to the quarter, the acquisition of Neuravi Limited, a privately held medical device company that develops and markets medical devices for neurointerventional therapy, was completed.

About Johnson & Johnson

Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 130,800 employees at more than 250 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

* Operational sales growth excluding the net impact of acquisitions and divestitures, as well as adjusted net earnings, adjusted diluted earnings per share and operational adjusted diluted earnings per share excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company’s website at www.investor.jnj.com. Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson’s results computed in accordance with GAAP.

Johnson & Johnson will conduct a conference call with investors to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com.

Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, a pharmaceutical pipeline of selected compounds in late stage development and a copy of today’s earnings call presentation can be found on the company’s website at www.investor.jnj.com.

NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the company to successfully execute strategic plans, including restructuring plans; market conditions and the possibility that the on-going share repurchase program may be delayed, suspended or discontinued; the impact of business combinations and divestitures, including the planned acquisition of Actelion Ltd.; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; increased scrutiny of the health care industry by government agencies; and the potential failure to meet obligations in compliance agreements with government bodies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 1, 2017, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.investor.jnj.com, or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
FIRST QUARTER
Percent Change
2017
2016
Total
Operations
Currency
Sales to customers by
segment of business
Consumer
U.S.
$
1,414
1,358
4.1
%
4.1
-
International
1,814
1,837
(1.3)
(1.6)
0.3
3,228
3,195
1.0
0.8
0.2
Pharmaceutical
U.S.
4,872
4,937
(1.3)
(1.3)
-
International
3,373
3,241
4.1
5.6
(1.5)
8,245
8,178
0.8
1.4
(0.6)
Medical Devices
U.S.
3,092
3,026
2.2
2.2
-
International
3,201
3,083
3.8
4.7
(0.9)
6,293
6,109
3.0
3.4
(0.4)
U.S.
9,378
9,321
0.6
0.6
-
International
8,388
8,161
2.8
3.6
(0.8)
Worldwide
$ 17,766
17,482
1.6
%
2.0
(0.4)
Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
FIRST QUARTER
Percent Change
2017
2016
Total
Operations
Currency
Sales to customers by
geographic area
U.S.
$
9,378
9,321
0.6
%
0.6
-
Europe
3,858
3,847
0.3
4.2
(3.9)
Western Hemisphere excluding U.S.
1,454
1,331
9.2
2.5
6.7
Asia-Pacific, Africa
3,076
2,983
3.1
3.4
(0.3)
International
8,388
8,161
2.8
3.6
(0.8)
Worldwide
$ 17,766
17,482
1.6
%
2.0
(0.4)
Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
FIRST QUARTER
2017
2016
Percent
Percent
Percent
Increase
Amount
to Sales
Amount
to Sales
(Decrease)
Sales to customers
$
17,766
100.0
$
17,482
100.0
1.6
Cost of products sold
5,386
30.3
5,329
30.5
1.1
Selling, marketing and administrative expenses
4,737
26.6
4,688
26.8
1.0
Research and development expense
2,060
11.6
2,013
11.5
2.3
Interest (income) expense, net
83
0.5
77
0.4
Other (income) expense, net
(160)
(0.9)
(39)
(0.2)
Restructuring
85
0.5
120
0.7
Earnings before provision for taxes on income
5,575
31.4
5,294
30.3
5.3
Provision for taxes on income
1,153
6.5
837
4.8
37.8
Net earnings
4,422
24.9
4,457
25.5
(0.8)
Net earnings per share (Diluted)
$
1.61
$
1.59
1.3
Average shares outstanding (Diluted)
2,754.5
2,803.8
Effective tax rate
20.7
%
15.8
%
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income
$
6,103
34.4
$
5,801
33.2
5.2
Net earnings
$
5,038
28.4
$
4,854
27.8
3.8
Net earnings per share (Diluted)
$
1.83
$
1.73
5.8
Effective tax rate
17.5
%
16.3
%
(1)See Reconciliation of Non-GAAP Financial Measures.
Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
First Quarter
% Incr. /
(Dollars in Millions Except Per Share Data)
2017
2016
(Decr.)
Earnings before provision for taxes on income - as reported
$
5,575
5,294
5.3
%
Intangible asset amortization expense
329
282
Restructuring/Other (1)
161
137
Litigation expense, net
-
66
AMO acquisition related cost
38
-
Other
-
22
Earnings before provision for taxes on income - as adjusted
$
6,103
5,801
5.2
%
Net Earnings - as reported
$
4,422
4,457
(0.8)
%
Intangible asset amortization expense
244
205
Restructuring/Other
121
120
Litigation expense, net
-
56
AMO acquisition related cost
251
-
Other
-
16
Net Earnings - as adjusted
$
5,038
4,854
3.8
%
Diluted Net Earnings per share - as reported
$
1.61
1.59
1.3
%
Intangible asset amortization expense
0.09
0.07
Restructuring/Other
0.04
0.04
Litigation expense, net
-
0.02
AMO acquisition related cost
0.09
-
Other
-
0.01
Diluted Net Earnings per share - as adjusted
$
1.83
1.73
5.8
%
Operational Diluted Net Earnings per share - as adjusted at 2015 foreign currency exchange rates
1.77
Impact of currency at 2016 foreign currency exchange rates
0.03
(0.04)
Operational Diluted Net Earnings per share - as adjusted at 2016 foreign currency exchange rates
$
1.86
1.73
7.5
%
(1) Includes $4M recorded in cost of products sold and $72M recorded in other (income) expense in the first quarter 2017 and $17M recorded in cost of products sold in the first quarter 2016.
Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Operational Sales Growth Excluding Acquisitions and Divestitures
FIRST QUARTER 2017 ACTUAL vs. 2016 ACTUAL
Segments
Consumer
Pharmaceutical
Medical Devices
Total
Operational %(1)
WW As Reported:
0.8%
1.4%
3.4%
2.0%
U.S.
4.1%
(1.3)%
2.2%
0.6%
International
(1.6)%
5.6%
4.7%
3.6%
Beauty
Vogue
(3.0)
(0.6)
U.S.
(6.3)
(0.9)
International
(0.7)
(0.1)
Other Neuroscience
Controlled Substance Raw Material and API Business
0.8
0.4
U.S.
0.9
0.5
International
0.5
0.2
Diagnostics
Ortho-Clinical Diagnostics
0.5
0.2
U.S.
0.0
0.0
International
1.0
0.4
Vision Care
Abbott Medical Optics
(2.0)
(0.7)
U.S.
(1.7)
(0.6)
International
(2.3)
(0.9)
All Other Acquisitions and Divestitures
(0.1)
(0.2)
(0.1)
U.S.
(0.7)
(0.7)
(0.3)
International
0.4
0.3
0.2
WW Ops excluding Acquisitions and Divestitures
(2.3)%
2.2%
1.7%
1.2%
U.S.
(2.9)%
(0.4)%
(0.2)%
(0.7)%
International
(1.9)%
6.1%
3.7%
3.4%
(1)Operational growth excludes the effect of translational currency
REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
% Change
2017
2016
Reported Operational (1) Currency
CONSUMER SEGMENT (2) (3)
BABY CARE
US
$
113
121
-6.6%
-6.6%
-
Intl
342
362
-5.5%
-6.1%
0.6%
WW
455
483
-5.8%
-6.3%
0.5%
BEAUTY
US
567
484
17.1%
17.1%
-
Intl
414
395
4.8%
5.0%
-0.2%
WW
981
879
11.6%
11.7%
-0.1%
ORAL CARE
US
156
170
-8.2%
-8.2%
-
Intl
206
215
-4.2%
-4.5%
0.3%
WW
362
385
-6.0%
-6.2%
0.2%
OTC
US
477
466
2.4%
2.4%
-
Intl
536
533
0.6%
0.7%
-0.1%
WW
1,013
999
1.4%
1.5%
-0.1%
WOMEN’S HEALTH
US
3
6
-50.0%
-50.0%
-
Intl
239
245
-2.4%
-4.2%
1.8%
WW
242
251
-3.6%
-5.3%
1.7%
WOUND CARE / OTHER
US
98
111
-11.7%
-11.7%
-
Intl
77
87
-11.5%
-12.3%
0.8%
WW
175
198
-11.6%
-11.9%
0.3%
TOTAL CONSUMER
US
1,414
1,358 4.1%
4.1%
-
Intl
1,814
1,837 -1.3%
-1.6%
0.3%
WW
$
3,228
3,195 1.0%
0.8%
0.2%
See footnotes at end of schedule
REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
% Change
2017
2016
Reported Operational (1) Currency
PHARMACEUTICAL SEGMENT (2) (3)
IMMUNOLOGY
US
$
2,123
2,171 -2.2%
-2.2%
-
Intl
807
739
9.2%
9.0%
0.2%
WW
2,930
2,910 0.7%
0.6%
0.1%
REMICADE
US
1,182
1,211 -2.4%
-2.4%
-
US Exports (4)
165
233
-29.2%
-29.2%
-
Intl
325
335
-3.0%
-4.8%
1.8%
WW
1,672
1,779 -6.0%
-6.3%
0.3%
SIMPONI / SIMPONI ARIA
US
229
216
6.0%
6.0%
-
Intl
199
174
14.4%
13.4%
1.0%
WW
428
390
9.7%
9.2%
0.5%
STELARA
US
547
511
7.0%
7.0%
-
Intl
276
224
23.2%
26.1%
-2.9%
WW
823
735
12.0%
12.9%
-0.9%
OTHER IMMUNOLOGY
US
-
-
-
-
-
Intl
7
6
16.7%
12.1%
4.6%
WW
7
6
16.7%
12.1%
4.6%
INFECTIOUS DISEASES
US
326
358
-8.9%
-8.9%
-
Intl
423
418
1.2%
2.8%
-1.6%
WW
749
776
-3.5%
-2.6%
-0.9%
EDURANT / RILPIVIRINE
US
12
11
9.1%
9.1%
-
Intl
137
108
26.9%
30.4%
-3.5%
WW
149
119
25.2%
28.3%
-3.1%
PREZISTA / PREZCOBIX / REZOLSTA
US
259
277
-6.5%
-6.5%
-
Intl
171
175
-2.3%
0.2%
-2.5%
WW
430
452
-4.9%
-3.9%
-1.0%
OTHER INFECTIOUS DISEASES
US
55
70
-21.4%
-21.4%
-
Intl
115
135
-14.8%
-15.9%
1.1%
WW
170
205
-17.1%
-17.8%
0.7%
REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
% Change
2017
2016
Reported Operational (1) Currency
NEUROSCIENCE
US
664
680
-2.4%
-2.4%
-
Intl
833
869
-4.1%
-2.9%
-1.2%
WW
1,497
1,549 -3.4%
-2.7%
-0.7%
CONCERTA / METHYLPHENIDATE
US
108
134
-19.4%
-19.4%
-
Intl
101
97
4.1%
4.2%
-0.1%
WW
209
231
-9.5%
-9.5%
0.0%
INVEGA SUSTENNA / XEPLION / TRINZA
US
372
305
22.0%
22.0%
-
Intl
232
208
11.5%
14.3%
-2.8%
WW
604
513
17.7%
18.8%
-1.1%
RISPERDAL CONSTA
US
95
95
0.0%
0.0%
-
Intl
112
136
-17.6%
-15.7%
-1.9%
WW
207
231
-10.4%
-9.3%
-1.1%
OTHER NEUROSCIENCE
US
89
146
-39.0%
-39.0%
-
Intl
388
428
-9.3%
-8.9%
-0.4%
WW
477
574
-16.9%
-16.6%
-0.3%
ONCOLOGY
US
664
549
20.9%
20.9%
-
Intl
930
805
15.5%
18.3%
-2.8%
WW
1,594
1,354 17.7%
19.3%
-1.6%
DARZALEX
US
201
101
99.0%
99.0%
-
Intl
54
-
*
*
0.0%
WW
255
101
*
*
0.0%
IMBRUVICA
US
190
132
43.9%
43.9%
-
Intl
219
129
69.8%
73.7%
-3.9%
WW
409
261
56.7%
58.6%
-1.9%
VELCADE
US
-
-
-
-
-
Intl
280
304
-7.9%
-5.0%
-2.9%
WW
280
304
-7.9%
-5.0%
-2.9%
ZYTIGA
US
233
272
-14.3%
-14.3%
-
Intl
290
286
1.4%
2.7%
-1.3%
WW
523
558
-6.3%
-5.6%
-0.7%
OTHER ONCOLOGY
US
40
44
-9.1%
-9.1%
-
Intl
87
86
1.2%
4.1%
-2.9%
WW
127
130
-2.3%
-0.4%
-1.9%
REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
% Change
2017
2016
Reported Operational (1) Currency
CARDIOVASCULAR / METABOLISM / OTHER
US
1,095
1,179 -7.1%
-7.1%
-
Intl
380
410
-7.3%
-4.5%
-2.8%
WW
1,475
1,589 -7.2%
-6.5%
-0.7%
XARELTO
US
513
567
-9.5%
-9.5%
-
Intl
-
-
-
-
-
WW
513
567
-9.5%
-9.5%
-
INVOKANA / INVOKAMET
US
247
297
-16.8%
-16.8%
-
Intl
37
28
32.1%
32.8%
-0.7%
WW
284
325
-12.6%
-12.5%
-0.1%
PROCRIT / EPREX
US
169
183
-7.7%
-7.7%
-
Intl
78
91
-14.3%
-13.1%
-1.2%
WW
247
274
-9.9%
-9.5%
-0.4%
OTHER
US
166
132
25.8%
25.8%
-
Intl
265
291
-8.9%
-5.4%
-3.5%
WW
431
423
1.9%
4.3%
-2.4%
TOTAL PHARMACEUTICAL
US
4,872
4,937
-1.3%
-1.3%
-
Intl
3,373
3,241
4.1%
5.6%
-1.5%
WW
$
8,245
8,178
0.8%
1.4%
-0.6%
See footnotes at end of schedule
REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
% Change
2017
2016
Reported
Operational (1) Currency
MEDICAL DEVICES SEGMENT (2)
CARDIOVASCULAR
US
$
259
231
12.1%
12.1%
-
Intl
240
212
13.2%
14.2%
-1.0%
WW
499
443
12.6%
13.1%
-0.5%
DIABETES CARE
US
154
180
-14.4%
-14.4%
-
Intl
245
249
-1.6%
-0.8%
-0.8%
WW
399
429
-7.0%
-6.5%
-0.5%
DIAGNOSTICS
US
-
-
-
-
-
Intl
1
28
**
**
**
WW
1
28
**
**
**
ORTHOPAEDICS
US
1,379
1,392
-0.9%
-0.9%
-
Intl
946
949
-0.3%
1.0%
-1.3%
WW
2,325
2,341
-0.7%
-0.2%
-0.5%
HIPS
US
209
203
3.0%
3.0%
-
Intl
143
139
2.9%
4.5%
-1.6%
WW
352
342
2.9%
3.5%
-0.6%
KNEES
US
246
244
0.8%
0.8%
-
Intl
152
145
4.8%
7.0%
-2.2%
WW
398
389
2.3%
3.1%
-0.8%
TRAUMA
US
391
381
2.6%
2.6%
-
Intl
251
261
-3.8%
-3.1%
-0.7%
WW
642
642
0.0%
0.3%
-0.3%
SPINE & OTHER
US
533
564
-5.5%
-5.5%
-
Intl
400
404
-1.0%
0.3%
-1.3%
WW
933
968
-3.6%
-3.1%
-0.5%
REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
% Change
2017
2016
Reported
Operational (1) Currency
SURGERY
US
995
981
1.4%
1.4%
-
Intl
1,276
1,247
2.3%
3.3%
-1.0%
WW
2,271
2,228
1.9%
2.5%
-0.6%
ADVANCED
US
392
352
11.4%
11.4%
-
Intl
485
464
4.5%
5.9%
-1.4%
WW
877
816
7.5%
8.3%
-0.8%
GENERAL
US
423
419
1.0%
1.0%
-
Intl
651
651
0.0%
1.2%
-1.2%
WW
1,074
1,070
0.4%
1.1%
-0.7%
SPECIALTY
US
180
210
-14.3%
-14.3%
-
Intl
140
132
6.1%
4.8%
1.3%
WW
320
342
-6.4%
-6.9%
0.5%
VISION CARE
US
305
242
26.0%
26.0%
-
Intl
493
398
23.9%
23.6%
0.3%
WW
798
640
24.7%
24.5%
0.2%
CONTACT LENSES / OTHER
US
256
242
5.8%
5.8%
-
Intl
427
398
7.3%
7.0%
0.3%
WW
683
640
6.7%
6.5%
0.2%
SURGICAL
US
49
-
**
**
-
Intl
66
-
**
**
0.0%
WW
115
-
**
**
0.0%
TOTAL MEDICAL DEVICES
US
3,092
3,026
2.2%
2.2%
-
Intl
3,201
3,083
3.8%
4.7%
-0.9%
WW
$
6,293
6,109
3.0%
3.4%
-0.4%
* Percentage greater than 100%
** Not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Prior year amounts have been reclassified to conform to current year product disclosure
(4) Reported as U.S. sales

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/johnson--johnson-reports-2017-first-quarter-results-300440779.html

SOURCE Johnson & Johnson

https://rt.prnewswire.com/rt.gif?NewsItemId=NY64145&Transmission_Id=201704180640PR_NEWS_USPR_____NY64145&DateId=20170418